Navigation Links
PAREXEL to Address New Regulatory Guidelines and Data Standards at DIA EuroMeeting
Date:3/22/2012

BOSTON, March 22, 2012 /PRNewswire/ -- Experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will advise biopharmaceutical companies on how to successfully navigate new regulatory guidelines and data standards requirements at the Drug Information Association (DIA) 24th Annual EuroMeeting. The meeting will be held March 26 - 28, 2012 in Copenhagen, Denmark.

Consultants from PAREXEL will be available at Stands 326 and 328 in the exhibit hall to discuss how the Company can help biopharmaceutical companies define and execute the most efficient regulatory approval paths for regional and international markets. Experts will also address how to institute strategic compliance measures and prepare for regulatory inspections.

Visitors to the PAREXEL stands can view demonstrations of the Perceptive Informatics eClinical Suite, which incorporates systems in compliance with regulatory guidelines. Perceptive Informatics eClinical solutions include the award-winning DataLabs® Electronic Data Capture (EDC) system, which enables a highly efficient clinical development process.

The DIA EuroMeeting program features the following sessions, which will be presented by PAREXEL experts:

Tuesday, March 27

  • Session 1004:  BRIDG - A Common Data Model for Internal and External System Interoperability, Terry Hardin, Director, Technology Integration and Data Standards (16:00)
  • Wednesday, March 28

  • Session 0806:  Chances and challenges of cell-based therapeutics, the new regulation 1394/2007NRalf Hess, PhD, MSc, Principal Consultant (11:00)
  • Session 0807:  Quality Requirements for Clinical TrialsNSusanne Franke, MSc, Senior Manager, Clinical Logistics (14:00)
  • Session 0808:  Metal Catalysts and Others: Analytical and Safety Assessment Demands for Pharmaceuticals Emerging from Regulatory GuidelinesÑAnders Neil, PhD, Principal Consultant (16:00)
  • For more information about PAREXEL visit www.PAREXEL.com or Stands 326 and 328 during the meeting. Information about the DIA EuroMeeting can be found at http://www.diahome.org.

    About PAREXEL International
    PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.

    This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
    For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

    PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts: Jennifer Baird, Senior Director of Public RelationsKim Leadley/Gene Carozza PAREXEL InternationalPAN CommunicationsTel: +781-434-4409Tel: + 617-502-4300Email: Jennifer.Baird@PAREXEL.comEmail: PAREXEL@pancomm.com


    '/>"/>
    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
    2. PAREXEL International to Present at Barclays Capital Healthcare Conference
    3. PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference
    4. PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
    5. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
    6. PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
    7. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
    8. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
    9. UCB and PAREXEL Sign Strategic Partnership Agreement
    10. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
    11. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... JOSE, Calif. , Feb. 11, 2016 /PRNewswire/ ... pioneered the use of the iFuse Implant System, ... fusion for certain disorders of the sacroiliac (SI) ... showing the cost benefits of MIS SI joint ... dysfunction due to degenerative sacroiliitis or SI joint ...
    (Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
    (Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. (NYSE ... has entered into an agreement with the University ... drug candidates in standard animal models of ocular ... Research Director. Dr. Romanowski has extensive experience in ... --> Eric Romanowski , Research Director. ...
    Breaking Medicine Technology:
    (Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Florida Hospital ... Lightning take on the St. Louis Blues at the Amalie Arena. The puck drops ... inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The MEGA Heart ...
    (Date:2/11/2016)... ... , ... The president released a FY 2017 budget request on Tuesday that ... the cost burden to military beneficiaries. , MOAA’s president, retired Air Force Lt. ... including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We were ...
    (Date:2/11/2016)... Petersburg, FL (PRWEB) , ... February 11, 2016 ... ... providers and advocates will discuss how to improve care by making data on ... pediatric heart disease. The Summit on Transparency and Public Reporting of Pediatric and ...
    (Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
    (Date:2/11/2016)... ... 11, 2016 , ... "What holds you back from ... a question as a challenge for his readers to examine the full scale ... (published by Partridge Singapore), Clarke explores the subject with more depth, revealing time-honored ...
    Breaking Medicine News(10 mins):